Compare IQIYI Inc - ADR (IQ) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IQIYI Inc - ADR vs Recursion Pharmaceuticals Inc — how do they compare? IQIYI Inc - ADR trades at $1 (market cap $979.50M), while Recursion Pharmaceuticals Inc trades at $3.98 (market cap $2.31B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 2.4× IQIYI Inc - ADR's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, IQIYI Inc - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IQIYI Inc - ADR for 55 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| IQ | RXRX | |
|---|---|---|
Market Cap | $979.50M | $2.31B |
Volume | 1,962,950 | 40,478,768 |
Sector | Media | Health |
52-Week High | $2.35 | $6.79 |
52-Week Low | $0.86 | $2.84 |
Typical Hold Time | 55 Days | 22 Days |
Enterprise Value | $2.47B | $1.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
iQIYI (IQ) trades at $1.01, showing no change in the latest session. The stock presents a mixed picture with strong analyst support (50% buy ratings) but concerning fundamentals including negative net income margins and declining revenue. Recent earnings have consistently beaten expectations despite losses, while the company is aggressively pursuing AI-driven content production to reset its cost structure amid streaming business contraction.
The outlook remains challenging with revenue declining to $27.3 billion in 2025 and projected to fall further to $26.0 billion in 2026. While valuation metrics appear attractive with P/S of 0.25 and P/B of 0.52, persistent losses and competitive pressures in Chinese streaming markets create significant headwinds. The AI content pivot offers potential but requires successful execution to justify current analyst optimism.
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IQIYI Inc - ADR
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
